Cemiplimab (Libtayo)
Revision as of 15:39, 2 October 2018 by Jwarner (talk | contribs) (Jwarner moved page Cemiplimab (REGN2810) to Cemiplimab (Libtayo): FDA approval)
Mechanism of action
From NCI Drug Dictionary: A human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1, PCD-1) protein, with potential immune checkpoint inhibitory and antineoplastic activity. Upon administration, cemiplimab binds to PD-1, inhibits its binding to the PD-1 ligand programmed cell death-1 ligand 1 (PD-L1), and prevents the activation of its downstream signaling pathways.
Diseases for which it is used
History of changes in FDA indication
- 9/28/2018: Initial approval "for patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation."
Also known as
- Code name: REGN2810
- Generic name: cemiplimab-rwlc
- Brand name: Libtayo